Sixty out of sixty stayed off their old medicines: a one-time cell therapy quiets multiple sclerosis

At the MSToronto congress this weekend, Bristol Myers Squibb shared early results for zola-cel, a therapy made from a patient's own immune cells, re-engineered in the lab to reset the immune attack that drives multiple sclerosis. In the Phase 1 Breakfree-2 study, 66 people whose MS kept advancing despite earlier treatments — 30 with relapsing disease, 36 with progressive forms — received the one-time infusion. Every patient treated at the higher dose (60 of 60) has been able to stay off their previous disease-modifying medicines since. Side effects were mostly brief and mild-to-moderate. It is Phase 1, so the road is long — but an immune reset, rather than lifelong suppression, is now a result doctors can point to, not just hope for.

SDG 3 · Good health and well-being — Mechanism: tech innovation